Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Cancer discovery - 1 Nov 2017

Song Chunying, Piva Marco, Sun Lu, Hong Aayoung, Moriceau Gatien, Kong Xiangju, Zhang Hong, Lomeli Shirley, Qian Jin, Yu Clarissa C, Damoiseaux Robert, Kelley Mark C, Dahlman Kimberley B, Scumpia Philip O, Sosman Jeffrey A, Johnson Douglas B, Ribas Antoni, Hugo Willy, Lo Roger S

Abstract excerpt

Treatment of advanced BRAFV600-mutant melanoma using a BRAF inhibitor or its combination with a MEK inhibitor typically elicits partial responses. We compared the transcriptomes of patient-derived tumors regressing on MAPK inhibitor (MAPKi) therapy against MAPKi-induced temporal transcriptomic states in human melanoma cell lines or murine melanoma in immune-competent mice. Despite heterogeneous dynamics of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocyte Common Antigens

Share to MAP Kinase Kinase 1

Share to Melanoma

Share to Melanoma, Experimental

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 28864476
DOI: 10.1158/2159-8290.CD-17-0401
PMCID: PMC6668729

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.PMID 28864476Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Multi-organ landscape of therapy-resistant melanomaSemantic proximity Read ↗

Temporal genomic analysis of melanoma rejection identifies regulators of tumor immune evasionSemantic proximity Read ↗

Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.Semantic proximity Read ↗

Multi-modal molecular programs regulate melanoma cell stateSemantic proximity Read ↗

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptationSemantic proximity Read ↗

<i>ZNF180</i> modulates tumor intrinsic immunotherapy resistance in melanoma through driving plasticitySemantic proximity Read ↗

Multi-model preclinical platform predicts clinical response of melanoma to immunotherapySemantic proximity Read ↗

Targeting the ERK/MAPK Pathway in Cancer: Oncogenic Mechanisms, Therapeutic Resistance, and Emerging Gene-Based StrategiesSemantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.Semantic proximity Read ↗

Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling PathwaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.